2026 Simcyp Workshops
Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…
Certara2026 年 6 月 11 日
QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials
QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…
Certara2026 年 6 月 11 日
Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations
2026 年 6 月 30 日 - 12:00 PM – 2:00 PM
Certara2026 年 6 月 10 日
Model Smarter, Not Harder: Introducing Model Designer
2026 年 6 月 30 日, 10:00 – 11:00 AM ET | 2026 年 7 月 2 日, 10:00 – 11:00…
Danielle Pillsbury2026 年 6 月 10 日
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.
Certara2026 年 6 月 9 日
The Case for Simulating Pregnancy
Pregnant women are routinely excluded from drug trials, leaving clinicians without dosing guidance. Discover how…
Certara2026 年 6 月 9 日
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients
See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…
Certara2026 年 6 月 4 日
Applying AI-Driven Biosimulation to Drug Discovery
Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…
Certara2026 年 6 月 2 日
Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib
This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…
Dorottya Gui-Bodnar2026 年 5 月 28 日
